INSM Jun 2024 20.000 call
| Previous close | 33.50 |
| Open | 30.83 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 20.00 |
| Expiry date | 2024-06-21 |
| Day's range | 30.83 - 33.50 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireInsmed to Host Commercial Webinar on June 4, 2024
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP).
- PR Newswire
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $650 million. I
ZacksInsmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
